Market Overview

Kite Reports Phase 1 ZUMA-3 Trial of KTE-C19 Showed 73% Of Patients Achieved Complete Remission of High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: FDA

 

Related Articles (KITE)

Partner Center